MAdaPARK: Feasibility of an Adapted Mindfulness Program to Parkinson's Disease

Sponsor
University Hospital, Bordeaux (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05622396
Collaborator
(none)
20
1
1
10.5
1.9

Study Details

Study Description

Brief Summary

The objective of this study is to determine the feasibility (primary objective) and the effects (secondary objectives) of an Mindfulness Based Stress Reduction (MBSR) program adapted specifically for patients with Parkinson's disease.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Mindfulness Based Stress Reduction
N/A

Detailed Description

In Parkinson's disease (PD) the psychological distress (anxiety and depression), is particularly impacting and often resistant to conventional drug treatment explaining the growing interest of patients in non-drug methods, such as mindfulness meditation. The Mindfulness Based Stress Reduction (MBSR) program has been evaluated in Parkinson's disease, showing main effects on anxiety and depression symptoms. These data remain, however, still fragile, particularly in terms of methodological robustness and number of patients involved and variable size of effects. A clinical trial was recently conducted at the Bordeaux University Hospital with 28 patients with Parkinson's disease . Preliminary results suggest that a program tailored specifically to the expectations and needs of patients with Parkinson's disease could, optimize accessibility, acceptability, and patient compliance for this type of approach while preserving clinical efficacy on anxiety and depression.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Pilot Feasibility Study of a Co-constructed Program (Patients - Experts) of Mindfulness Meditation Adapted to Patients With Parkinson's Disease.
Actual Study Start Date :
Jan 16, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: MBSR program adapted

8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews

Procedure: Mindfulness Based Stress Reduction
Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.

Outcome Measures

Primary Outcome Measures

  1. Assess MBSR program [Month 4]

    The rate of patients who have completed the entire MBSR program "adapted"

Secondary Outcome Measures

  1. Attendance rate [Month 3]

    Number of days of practice and daily meditation time.

  2. Program tolerance [month 1 at month 2]

    Number of side effects and the difficulties

  3. Relevance of the adaptations put in place [month 3]

    It will be evaluated from the analysis of feelings and impressions of patients . These different elements will be obtained from the analysis of the semi-directed interviews (qualitative analysis).

  4. Beck Depression Inventory [Day 0 and month 3]

    Assessment depressive symptoms, minimum value 0 and maximum value 36

  5. Parkinson Anxiety Scale (PAS) [Day 0 and month 3]

    Assessment anxiety symptoms,minimum value 0 and maximum value 48

  6. Parkinson's Disease Sleep Scale [Day 0 and month 3]

    Assessment sleep, minimum value 0 and maximum value 60

  7. Parkinson Disease Questionnaire [Day 0 and month 3]

    Assessment quality of life, minimum value 0 and maximum value 156

  8. Movement Disorder Society Unified Parkinson Disease Rating Scale [Day 0 and month 3]

    Assessment motor and non-motor symptoms of Parkinson Disease

  9. King's college Parkinson's disease Pain Scale [Day 0 and month 3]

    Assessment pain, minimum value 0 and maximum value 168

  10. Number of Anti-parkinsonian and psychotropic treatments [Day 0 and month 3]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 79 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient suffering from Parkinson's disease,

  • Patient aged over 18 and under 80,

  • Patient with a Hoehn and Yahr Stage of 1 to 3,

  • Patient affiliated or beneficiary of the social security system,

  • Patient having signed a free, informed and written consent

Exclusion Criteria:
  • Patient with severe motor fluctuations (i.e. scoring 4 to at least one of the following items of part IV of the Movement Disorder Society Unified Parkinson Disease Rating Scale: 4.1 and 4.2 for dyskinesias; 4.3, 4.4 and 4.5 for motor fluctuations),

  • Patient with acute depression not stabilized by treatment or dating from less than 6 months,

  • Patient with non-stabilized psycho-behavioral disorders (hallucinations, psychoses, impulse control disorders) dating from less than 6 months,

  • Patient with major cognitive impairment (Montreal Cognitive Assessment ≤24),

  • Patient who has already participated in a structured mindfulness meditation program

  • Patient placed under judicial safeguard, guardianship or curator ship,

  • Pregnant or breastfeeding women.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xavier Arnozan Hospital Pessac France 33600

Sponsors and Collaborators

  • University Hospital, Bordeaux

Investigators

  • Principal Investigator: François TISON, Pr, Université Hospital, Bordeaux

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT05622396
Other Study ID Numbers:
  • CHUBX 2022/54
First Posted:
Nov 18, 2022
Last Update Posted:
Jan 23, 2023
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Bordeaux
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 23, 2023